Skip to content
Search

Latest Stories

BREAKING: GPhC proposes 39 per cent hike in pharmacy premises registration fees; NPA critical

The National Pharmacy Association has vehemently opposed General Pharmaceutical Council's latest proposal to increase registration fees for pharmacy premises by a whopping 39 per cent.

In it's response to the GPhC’s Consultation on the draft 2020 fees rules proposed todaythe NPA said it couldn't "possibly support" such a "big percentage increase at a time when community pharmacy finances are already under immense pressure."


"GPhC says it needs to cover its costs, however pharmacy contractors are bound to ask if the regulator is working as hard as pharmacies themselves to deliver efficiencies. We will now take soundings from NPA members and give our formal, detailed response to GPhC in March,” the pharmacy body said.

Pharmaceutical Services Negotiating Committee (PSNC) Chief Executive Simon Dukes said: “PSNC works collaboratively with the GPhC; we recognise the importance of regulation and we support the need for that function to be properly funded. However, any further increase in costs for community pharmacy contactors comes at a particularly difficult time when businesses are already facing significant financial challenges from a combination of rising costs, capacity issues and flat funding".

The pharmacy regulator is proposing to raise the registration and renewal fees for pharmacy premises from £262 to £365. However, GPhC has clarified that there are no plans to increase fees for pharmacists or technicians as part of the consultation.

GPhC Chief Executive Duncan Rudkin said: “We recognise the financial pressures that pharmacy owners are under and any uplift in fees is only proposed when necessary.”

Rudkin said the changes were for a robust and sustainable financial framework with fees that reflect the true cost of regulation.

“Since 2013, we have introduced significant changes in how we regulate and inspect pharmacies, improving the effectiveness of our regulatory approach and bringing benefits to patients, the public and pharmacies,” he said.

The first phase of the consultation runs from today until the end of March. If adopted, the new arrangements would come into place from October.

When asked by Pharmacy Business, the Royal Pharmaceutical Society (RPS) said it would submit a formal response to the GPhC proposal after consulting with its members across the UK.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less